Background
==========

The Alberta Kidney Disease Network (AKDN) is a collaborative group of nephrology researchers located in Calgary and Edmonton, Alberta, Canada, with a mission to undertake clinical research and offer research training in kidney disease. The flagship initiative of the AKDN is a unique data collection initiative of routine laboratory tests on all patients in the province of Alberta, resulting in a geographically inclusive database. Patients identified from laboratory data are linked to administrative and other computerized sources to obtain detailed information including socio-demographic data, clinical data including comorbidities, health care encounters, health care costs, death, and kidney-related outcomes.

As the initiative grows the AKDN research findings and activities are beginning to appear more frequently in peer-reviewed literature and health policy circles \[[@B1]-[@B3]\]. However, a detailed description of the network\'s objectives, details of the laboratory database and linked data sources, as well as the process for ongoing patient data collection has not been published. This paper provides such a description, and includes examples of research undertaken as well as future research opportunities for the AKDN.

Objectives of the AKDN
----------------------

The AKDN objectives are focused around key research methodologies: clinical epidemiology; health services research; clinical trials; systematic review and meta-analysis; and health economics. Five specific aims relevant to the AKDN dataset were initially identified:

1\. To determine the prevalence and identify those at high risk for chronic kidney disease in Alberta, Canada.

2\. To determine rates of progression of chronic kidney disease.

3\. To determine if access to/quality of specialized medical care and/or rates of progression of kidney disease differs by gender, age, location of residence or ethnic background.

4\. To determine the health care costs of caring for patients with chronic kidney disease.

5\. To determine optimal treatments for patients with chronic kidney disease.

This is not an exhaustive list, and as the Network grows more objectives and research questions are being addressed. The examples of on-going research projects outlined below demonstrate the potential of this data source.

The AKDN has also developed a plan to facilitate implementation of its research findings. These knowledge translation activities target patients, health care providers, researchers and health policy-makers. These activities aim to provide information to patients regarding kidney function and disease in general, health care providers to assist with investigation and management of patients with chronic kidney disease, and policy makers to guide evaluation and planning of health service delivery for patients with chronic kidney disease. A website <http://www.AKDN.info> was established to facilitate knowledge translation activities, as well as to provide information regarding team members, training opportunities and research activities.

Construction and Content
========================

Laboratory Database Overview
----------------------------

The core component of the AKDN database is the central repository of laboratory data. Through the AKDN, and in collaboration with laboratories across the province of Alberta (population 3.5 million), we have developed a process for retrieval, storage and maintenance of computerized laboratory data and relevant laboratory tests for all patients who have these measurements obtained throughout the province. To permit complete collection of specific tests, and in accordance with privacy laws and ethics board regulations, we were required to limit the number of laboratory tests retrieved and maintained in the database. As such we selected tests which are routinely ordered for patients with common medical conditions to guide ongoing patient assessment, monitor disease progression and identify relevant outcomes (Table [1](#T1){ref-type="table"}). The data elements (Table [2](#T2){ref-type="table"}) include, in addition to details of the test, a unique patient identifier used for linkage with other data sources. Location of the test (in-versus out-patient) is important to differentiate test results obtained during a hospitalization (potentially influenced by an acute illness), from those obtained in the out-patient setting (which may better reflect stable medical conditions).

###### 

Laboratory tests collected within the AKDN database

  Serum Tests:
  -------------------------------------
  Creatinine
  Hemoglobin
  Potassium
  Hemoglobin A1C
  Fasting total cholesterol
  Fasting high density lipoprotein
  Fasting low density lipoprotein
  **Urine Tests:**
  Urine dipstick
  Urine microalbumin-creatinine ratio
  Urine protein-creatinine ratio
  24 hour urine protein

###### 

Data elements in the AKDN laboratory component of the database

  Data elements:
  ---------------------------------------
  Unique patient identifier
  Patient date of birth
  Patient gender
  Test name
  Test result
  Test date
  Health region
  Location of test (in- or out-patient)

Measurement of kidney function
------------------------------

The serum creatinine is used to obtain an estimate of glomerular filtration rate (eGFR). Serum creatinine measurements \< 25 umol/L are excluded as they are physiologically implausible. We initially used the non-isotope dilution mass spectrometry traceable 4-variable Modification of Diet in Renal Disease (MDRD) Study equation \[[@B4]\] to estimate GFR, however beginning in 2003 Alberta laboratories began transitioning to methods for creatinine analysis calibrated against an isotope dilution mass spectrometry (IDMS) reference standard. For these creatinine measurements the new version of the MDRD formula derived for use with isotope dilution mass spectrometry traceable creatinine measurements is used \[[@B5]\]. The linear relationship between the old and new methods for estimating GFR was established, thus ensuring accuracy of estimates with these changes in methods over time. To reduce inter-laboratory variation in eGFR creatinine measurements are standardized across provincial laboratories to an IDMS reference standard, and a laboratory-specific correction factor is applied where necessary. Furthermore, we have previously reported minimal intra-laboratory variation of eGFR estimates over time \[[@B6]\]. Although data on race is not available, misclassification of eGFR is expected to be minimal as \< 1% of the Alberta population includes individuals of black race \[[@B7]\].

To reduce the effect of regression to the mean, a statistical phenomenon that occurs when repeated measurements with wide variability are made on the same subject \[[@B8]\], baseline kidney function (index eGFR) is estimated using all out-patient serum creatinine measurements taken within a six-month period of the first creatinine measurement, with the index eGFR defined as the mean of the measurements in this six-month period. The date of the last serum creatinine measurement in the six month period, for subjects with more than a single measurement, is used as the index date. Other definitions of baseline kidney function however can be employed, depending on the objectives of the particular study.

Proteinuria, an important predictor of outcomes for patients with kidney disease, is captured by qualitative (urine dipstick) as well as quantitative measures (Table [1](#T1){ref-type="table"}). There is considerable variation in guidelines as to the threshold to define clinical significant proteinuria. Our current approach to categorizing urinary protein concentration (Table [3](#T3){ref-type="table"}) is based on that proposed by Lamb et al\[[@B9]\].

###### 

Classification of urinary albumin and protein concentration

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification                                 Urine albumin:creatinine ratio\   Urine protein:creatinine ratio\   24 hour urine microalbumin\   24 hour urine protein\   Urine dipstick
                                                 (mg/mmol)                         (mg/mmol)                         (mg/day)                      (mg/day)                 
  ---------------------------------------------- --------------------------------- --------------------------------- ----------------------------- ------------------------ ----------------
  **Normal**                                     ≤ 2.5 men\                        \< 15                             ≤ 30.0                        \< 150.0                 Negative
                                                 ≤ 3.5 women                                                                                                                

                                                                                                                                                                            

  **Microalbuminuria/Minimal proteinuria**       2.6-29.9 men\                     15.0-49.9                         31.0-299.9                    150.0-299.9              Trace
                                                 3.6-29.9 women                                                                                                             

                                                                                                                                                                            

  **Macroalbuminuria/Proteinuria**               30.0-69.9                         50.0-99.9                         300.0-699.9                   300.0-999.9              1^+^

                                                                                                                                                                            

  **Heavy macroalbuminuria/Heavy proteinuria**   70.0-315.9                        100.0-450.9                       700.0-2449.9                  1000.0-3499.9            2^+^

                                                                                                                                                                            

  **Nephrotic range**                            \> = 316                          ≥ 451.0                           ≥ 2450.0                      ≥ 3500.0                 3^+^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adapted from Lamb EJ et al \[[@B9]\].

Linked Data Sources
-------------------

Linkage of laboratory data to administrative and other computerized data sources provides a rich source of information for assessment of socio-demographic characteristics, clinical variables and health outcomes (Figure [1](#F1){ref-type="fig"}). The unique patient identifier is used to link the laboratory data to a number of such computerized data sources including Alberta Health and Wellness (AHW) administrative data, Alberta Bureau of Vital Statistics, the Northern and Southern Alberta Renal program databases \[[@B10]\], as well as other databases related to program delivery such as the Chronic Disease Management database. All data is available electronically, thus there is no requirement for manual data entry.

![**Data sources and variables linked to the Alberta Kidney Disease Network laboratory data**.](1471-2369-10-30-1){#F1}

AHW administrative data includes all residents of the province of Alberta, and contains data sources which permit determination of disease incidence and prevalence using validated algorithms for common medical conditions such as hypertension, diabetes, acute myocardial infarction, congestive heart failure and stroke \[[@B11]-[@B15]\], as well as assessment of clinical, health outcomes and costing information. In addition to routine demographic information and dates of death, the AHW Registry file includes information to permit the assessment of Aboriginal \[[@B2]\], Chinese \[[@B16]\] and South Asian \[[@B17]\] ethnicity, socio-economic status \[[@B18]\], and a six-digit postal code which enables unique geographic information system (GIS) analyses to be performed \[[@B19],[@B20]\].

Alberta Blue Cross administers extended health benefits paid by AHW on behalf of eligible individuals, including residents aged 65 and older, for services which include formulary drugs, permitting evaluation of drug use and its impact on outcomes \[[@B21],[@B22]\]. Details regarding ambulatory care encounters including emergency department visits are obtained from the ambulatory care file, while in-patient hospitalization information (including diagnostic and procedure codes using ICD-9-CM until March 31 2002 followed by ICD-10) is retrieved from the hospitalization file. The physician claims file provides detailed information on all physician encounters, including up to 3 ICD-9 diagnostic codes. The physician claims and hospitalization files are used to define diabetes mellitus and hypertension following validated algorithms \[[@B11],[@B12]\], with other comorbid conditions based on a validated coding algorithm for Charlson comorbidites using ICD-9-CM and ICD-10 codes \[[@B23]\]. The presence of one or more diagnostic code in any position up to 3 years prior to study entry is used for identification of comorbidities.

Follow-up and capture of outcomes of particular relevance for the study of kidney disease, including dialysis initiation or kidney transplantation, is possible by linkage with the Northern and Southern Alberta Renal Program databases \[[@B10]\]. These two programs collectively provide care to all patients with end-stage renal disease in the province. Information on end-stage renal disease status from this clinical database is supplemented by identifying additional long-term dialysis patients from administrative data based on an algorithm for ICD-9-CM codes from physician claims \[[@B24]\].

Technical Specifications
------------------------

As outlined in Figure [1](#F1){ref-type="fig"}, the database consists of linked individual components. The AKDN database operates in a limited access computing environment with a single database server for storage of the data located in Calgary. The AKDN uses the Calgary Health Region server for data storage which maintains security standards required for individual patient level data. Currently the database operates on a Windows operating system. All client computers are personal computers with secure access. All personal identifiers are stripped from the database prior to their use for research purposes to protect patient confidentiality.

Strengths and Limitations in Use of Laboratory Data for Research Purposes
-------------------------------------------------------------------------

Laboratory data can be used for case identification and for assessment of disease control, including the use of hemoglobin A1C among patients with diabetes, cholesterol levels among patients at risk for cardiovascular disease, and hemoglobin levels among patients with chronic diseases. It can also be used to identify adverse outcomes related to a treatment or procedure, such as the development of hyperkalemia among patients initiating an angiotensin converting enzyme inhibitor or angiotensin receptor blocker medication. Importantly the serum creatinine measurement can be used to estimate kidney function and define chronic kidney disease, and thus can be used for ongoing surveillance (defined as the ongoing systematic and population-based collection of data).

Surveillance is important for the purposes of disease detection, assessment of trends, identification of service needs for program and policy development, and research. Recently efforts have been directed towards enhanced surveillance for specific chronic medical conditions, including diabetes, cardiovascular disease, and chronic kidney disease. However, the ability to implement a comprehensive surveillance system is limited by the availability of data, and sources currently used often include outcome measures only (such as hospitalization or mortality), or are limited by incomplete assessment of comorbidity. The computerized laboratory data within the AKDN provides the potential for both case identification and ongoing monitoring of chronic medical conditions such as chronic kidney disease (using the serum creatinine to estimate glomerular filtration rate), and can be enhanced to obtain an assessment of comorbidity through linkage with administrative data.

Notwithstanding its strengths, there are important limitations which must be recognized when using the AKDN data. First, the use of laboratory data to define a study cohort by definition will limit the study to subjects who have sought medical care and had a laboratory test undertaken. Although the reasons for measurement are unknown and selected patients may differ from patients without these measurements, this is unlikely to invalidate study findings which are based upon a large proportion of patients from the source population and reflect standard clinical practices in a defined geographic location with universal access to health care. Furthermore a cohort identified by laboratory-based case finding is easily generalized to primary care practice. Second, use of administrative data limits access to certain clinical variables such as blood pressure control and lifestyle factors (smoking, exercise and diet), which may be potential confounders. However other important confounders such as diabetes, hypertension and the Charlson comorbidity index are captured using the computerized data sources.

Utility and Discussion
======================

The AKDN has used this database to gain a more in-depth understand of chronic kidney disease at the community level, including prevalence and progression of kidney dysfunction \[[@B6],[@B25]\] and aspects of health care delivery for chronic kidney disease \[[@B2],[@B3]\]. Risk factor assessment has also been examined, including the association between drug use and progression of kidney dysfunction \[[@B21],[@B22]\] as well as the impact of anemia on patient outcomes \[[@B1]\]. Other research questions are being explored, including the economic impact of population based screening for chronic kidney disease, the long term outcomes for patients with radio-contrast induced acute kidney injury, and several studies exploring the association between residence location and health outcomes. To date primary users of the database have included both clinician researchers and graduate students within the AKDN. We are currently exploring options for external data requests, which must take into account provincial privacy and security laws.

Conclusion
==========

The AKDN has developed a unique repository of laboratory data which can be used for health services and health policy research. Although originally developed by nephrology researchers, the AKDN database includes information on all patients who have obtained routine laboratory investigations (not just those with kidney disease), and therefore could also be used for the study of other chronic medical conditions.
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